These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35580766)

  • 1. A novel high-throughput screening strategy for targeting alpha-synuclein and other long-lived proteins.
    Casalino E; Stine LB; Corin AJ; Thai CT; Quiroz J; Wilson SC; Labow M; Mittal S
    SLAS Discov; 2022 Sep; 27(6):349-357. PubMed ID: 35580766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of SNCA Cell Models Using Zinc Finger Nuclease (ZFN) Technology for Efficient High-Throughput Drug Screening.
    Dansithong W; Paul S; Scoles DR; Pulst SM; Huynh DP
    PLoS One; 2015; 10(8):e0136930. PubMed ID: 26317803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
    Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
    Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Throughput Screening Methodology to Identify Alpha-Synuclein Aggregation Inhibitors.
    Pujols J; Peña-Díaz S; Conde-Giménez M; Pinheiro F; Navarro S; Sancho J; Ventura S
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activators of alpha synuclein expression identified by reporter cell line-based high throughput drug screen.
    Stahl F; Denner P; Piston D; Evert BO; de Boni L; Schmitt I; Breuer P; Wüllner U
    Sci Rep; 2021 Oct; 11(1):19857. PubMed ID: 34615900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel tool for monitoring endogenous alpha-synuclein transcription by NanoLuciferase tag insertion at the 3'end using CRISPR-Cas9 genome editing technique.
    Basu S; Adams L; Guhathakurta S; Kim YS
    Sci Rep; 2017 Apr; 8():45883. PubMed ID: 28374838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
    Sharma N; Rao SP; Kalivendi SV
    Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The AKT modulator A-443654 reduces α-synuclein expression and normalizes ER stress and autophagy.
    Gandelman M; Dansithong W; Kales SC; Paul S; Maag G; Aoyama E; Zakharov A; Rai G; Dexheimer T; Whitehill BM; Sun H; Jadhav A; Simeonov A; Henderson MJ; Huynh DP; Pulst SM; Scoles DR
    J Biol Chem; 2021 Oct; 297(4):101191. PubMed ID: 34520759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
    Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
    J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (α-syn) oligomerization and secretion.
    von Einem B; Eschbach J; Kiechle M; Wahler A; Thal DR; McLean PJ; Weishaupt JH; Ludolph AC; von Arnim CAF; Danzer KM
    Aging (Albany NY); 2017 Jul; 9(7):1677-1697. PubMed ID: 28722658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.
    Gupta V; Salim S; Hmila I; Vaikath NN; Sudhakaran IP; Ghanem SS; Majbour NK; Abdulla SA; Emara MM; Abdesselem HB; Lukacsovich T; Erskine D; El-Agnaf OMA
    Sci Rep; 2020 May; 10(1):8137. PubMed ID: 32424162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease.
    Harischandra DS; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Toxicol Sci; 2015 Feb; 143(2):454-68. PubMed ID: 25416158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening.
    Henderson-Smith A; Chow D; Meechoovet B; Aziz M; Jacobson SA; Shill HA; Sabbagh MN; Caviness JN; Adler CH; Driver-Dunckley ED; Beach TG; Yin H; Dunckley T
    PLoS One; 2013; 8(10):e77711. PubMed ID: 24204929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
    Sahay S; Ghosh D; Singh PK; Maji SK
    Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A sensitive assay reveals structural requirements for α-synuclein fibril growth.
    Dhavale DD; Tsai C; Bagchi DP; Engel LA; Sarezky J; Kotzbauer PT
    J Biol Chem; 2017 Jun; 292(22):9034-9050. PubMed ID: 28373279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
    El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
    FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
    Mehra S; Sahay S; Maji SK
    Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of SNCA variants with α-synuclein of gastric and colonic mucosa in Parkinson's disease.
    Chung SJ; König IR; Lohmann K; Hinrichs F; Kim J; Ryu HS; Lee HJ; Kim K; Lee JH; Jung KW; Kim MJ; Kim MJ; Kim YJ; Yun SC; Hong SM; Myung SJ; Klein C
    Parkinsonism Relat Disord; 2019 Apr; 61():151-155. PubMed ID: 30424941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?
    Kanaan NM; Manfredsson FP
    J Parkinsons Dis; 2012; 2(4):249-67. PubMed ID: 23938255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.